PL1989200T3 - Pochodne [4-(benzo[b]tiofen-2-ylo)-pirymidyn-2-ylo] aminy jako inhibitory IKK-beta do leczenia raka i chorób zapalnych - Google Patents

Pochodne [4-(benzo[b]tiofen-2-ylo)-pirymidyn-2-ylo] aminy jako inhibitory IKK-beta do leczenia raka i chorób zapalnych

Info

Publication number
PL1989200T3
PL1989200T3 PL06850430T PL06850430T PL1989200T3 PL 1989200 T3 PL1989200 T3 PL 1989200T3 PL 06850430 T PL06850430 T PL 06850430T PL 06850430 T PL06850430 T PL 06850430T PL 1989200 T3 PL1989200 T3 PL 1989200T3
Authority
PL
Poland
Prior art keywords
ikk
thiophen
pyrimidin
benzo
cancer
Prior art date
Application number
PL06850430T
Other languages
English (en)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL1989200T3 publication Critical patent/PL1989200T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06850430T 2005-11-18 2006-11-15 Pochodne [4-(benzo[b]tiofen-2-ylo)-pirymidyn-2-ylo] aminy jako inhibitory IKK-beta do leczenia raka i chorób zapalnych PL1989200T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
EP06850430A EP1989200B1 (en) 2005-11-18 2006-11-15 [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
PL1989200T3 true PL1989200T3 (pl) 2009-12-31

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06850430T PL1989200T3 (pl) 2005-11-18 2006-11-15 Pochodne [4-(benzo[b]tiofen-2-ylo)-pirymidyn-2-ylo] aminy jako inhibitory IKK-beta do leczenia raka i chorób zapalnych

Country Status (27)

Country Link
US (1) US7547691B2 (pl)
EP (1) EP1989200B1 (pl)
JP (1) JP2009516697A (pl)
KR (1) KR100990771B1 (pl)
CN (1) CN101309918B (pl)
AR (1) AR057911A1 (pl)
AT (1) ATE437873T1 (pl)
AU (1) AU2006337626B2 (pl)
BR (1) BRPI0618245A2 (pl)
CA (1) CA2629336A1 (pl)
CR (1) CR9947A (pl)
DE (1) DE602006008187D1 (pl)
DK (1) DK1989200T3 (pl)
EA (1) EA014426B1 (pl)
EC (1) ECSP088456A (pl)
ES (1) ES2329085T3 (pl)
IL (1) IL190489A0 (pl)
MA (1) MA30053B1 (pl)
NO (1) NO20082594L (pl)
PE (1) PE20070833A1 (pl)
PL (1) PL1989200T3 (pl)
PT (1) PT1989200E (pl)
SI (1) SI1989200T1 (pl)
TN (1) TNSN08227A1 (pl)
TW (1) TW200800201A (pl)
WO (1) WO2007092095A2 (pl)
ZA (1) ZA200803940B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2007752T3 (da) 2006-03-31 2010-11-15 Janssen Pharmaceutica Nv Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
US8063212B2 (en) * 2006-12-21 2011-11-22 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
JP5166441B2 (ja) 2006-12-21 2013-03-21 イーライ リリー アンド カンパニー 癌治療用イミダゾリジノニルアミノピリミジン化合物
KR101131261B1 (ko) 2007-05-16 2012-04-24 일라이 릴리 앤드 캄파니 트리아졸릴 아미노피리미딘 화합물
MX2009012233A (es) 2007-05-16 2009-12-01 Lilly Co Eli Compuestos de triazolil aminopirimidina.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
ME02154B (me) 2008-06-30 2015-10-20 Janssen Pharmaceutica Nv Proces za pripremu supstituisanih derivata pirimidina
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011134140A1 (en) 2010-04-27 2011-11-03 Hutchison Medipharma Limited Pyrimidinyl indole compounds
JP2014512364A (ja) 2011-04-07 2014-05-22 コーネル ユニバーシティー 水溶液中で二量体化できる単量体、およびその使用法
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
WO2013119895A1 (en) * 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
SG11201900687VA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) * 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法

Also Published As

Publication number Publication date
US7547691B2 (en) 2009-06-16
PE20070833A1 (es) 2007-08-27
PT1989200E (pt) 2009-10-12
SI1989200T1 (sl) 2009-12-31
ECSP088456A (es) 2008-06-30
EP1989200B1 (en) 2009-07-29
ZA200803940B (en) 2009-09-30
NO20082594L (no) 2008-06-10
AU2006337626A8 (en) 2008-06-19
DE602006008187D1 (de) 2009-09-10
CN101309918B (zh) 2010-12-29
TW200800201A (en) 2008-01-01
DK1989200T3 (da) 2009-11-09
KR20080059451A (ko) 2008-06-27
EA014426B1 (ru) 2010-12-30
ATE437873T1 (de) 2009-08-15
EP1989200A2 (en) 2008-11-12
JP2009516697A (ja) 2009-04-23
US20080306082A1 (en) 2008-12-11
EA200801362A1 (ru) 2009-02-27
AR057911A1 (es) 2007-12-26
IL190489A0 (en) 2008-11-03
TNSN08227A1 (en) 2009-10-30
AU2006337626B2 (en) 2012-03-22
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
WO2007092095A2 (en) 2007-08-16
CN101309918A (zh) 2008-11-19
BRPI0618245A2 (pt) 2011-08-23
MA30053B1 (fr) 2008-12-01
WO2007092095A3 (en) 2007-11-08
ES2329085T3 (es) 2009-11-20
CR9947A (es) 2008-11-28
KR100990771B1 (ko) 2010-10-29

Similar Documents

Publication Publication Date Title
PL1989200T3 (pl) Pochodne [4-(benzo[b]tiofen-2-ylo)-pirymidyn-2-ylo] aminy jako inhibitory IKK-beta do leczenia raka i chorób zapalnych
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
HK1143804A1 (zh) 用於治療線粒體疾病的 -醌基 -羥基丁酰胺衍生物
IL194425A0 (en) N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
IL201537A0 (en) Heteroaryl substituted pyarzole derivatives useful for treating hyper- proliferative disorders and diseases associated with angiogenesis
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL210055A0 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
ZA200809024B (en) 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
EP2237664A4 (en) (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
HK1125631A1 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP2324029A4 (en) HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT
WO2009011850A3 (en) Novel therapeutic compounds
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
NZ602041A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
ZA200710605B (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
EP2235004A4 (en) INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
HK1117402A1 (en) Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders
IL197504A0 (en) ISOSERINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR IXa
ZA201002807B (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents